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Gamma interferon (IFN-) induces expression of the tryptophan-catabolizing enzyme indoleamine 2,3-
dioxygenase (IDO1) in human epithelial cells, the permissive cells for the obligate intracellular bacterium
Chlamydia trachomatis. IDO1 depletes tryptophan by catabolizing it to kynurenine with consequences for C.
trachomatis, which is a tryptophan auxotroph. In vitro studies reveal that tryptophan depletion can result in the
formation of persistent (viable but noncultivable) chlamydial forms. Here, we tested the effects of the IDO1
inhibitor, levo-1-methyl-tryptophan (L-1MT), on IFN--induced C. trachomatis persistence. We found that
addition of 0.2 mM L-1MT to IFN--exposed infected HeLa cell cultures restricted IDO1 activity at the
mid-stage (20 h postinfection [hpi]) of the chlamydial developmental cycle. This delayed tryptophan depletion
until the late stage (38 hpi) of the cycle. Parallel morphological and gene expression studies indicated a
consequence of the delay was a block in the induction of C. trachomatis persistence by IFN-. Furthermore,
L-1MT addition allowed C. trachomatis to undergo secondary differentiation, albeit with limited productive
multiplication of the bacterium. IFN--induced persistent infections in epithelial cells have been previously
reported to be more resistant to doxycycline than normal productive infections in vitro. Pertinent to this
observation, we found that L-1MT significantly improved the efficacy of doxycycline in clearing persistent C.
trachomatis forms. It has been postulated that persistent forms of C. trachomatis may contribute to chronic
chlamydial disease. Our findings suggest that IDO1 inhibitors such as L-1MT might provide a novel means to
investigate, and potentially target, persistent chlamydial forms, particularly in conjunction with conventional
therapeutics.
Chlamydia trachomatis is an obligate intracellular bacterium
that has a tropism for the columnar epithelial cells of the
conjunctiva (serovars A to C) and the urogenital tract (sero-
vars D to K) (42). Most C. trachomatis infections are asymp-
tomatic and therefore remain undetected (36). While many
individuals eventually clear infection, clearance can take sev-
eral months to several years (25, 26). If left untreated, C.
trachomatis infections can progress to chronic inflammatory
disease. Chronic ocular infection can result in trachoma, one of
the leading causes of preventable blindness (43, 55). C. tracho-
matis is also the major bacterial sexually transmitted agent
worldwide, commonly infecting the male urethra and female
endocervix (42). Bacteria can ascend from the endocervix into
the endometrium and fallopian tubes; chronic infection at
these sites is associated with pelvic inflammatory disease (PID)
and salpingitis, potentially resulting in tubal infertility or ecto-
pic pregnancy (reviewed in reference 13). The pathological
sequelae observed during chronic C. trachomatis infections
have been proposed to result from the induction of a sustained
inflammatory response to persistent bacteria (43). “Chlamydial
persistence” in vitro has been described as an alternative phase
of the chlamydial developmental cycle in which bacteria enter
a morphologically distinct viable but noncultivable growth
stage that can result in a long-term relationship with their host
cells (8). Indirect evidence that C. trachomatis could persist in
vivo in this altered growth state arises from studies describing
the detection of chlamydial antigen and nucleic acid in tissues
in the absence of cultivability (22, 35) and documentation of
recurrent chlamydial disease when reinfection was unlikely
(18, 54).
The C. trachomatis developmental cycle is biphasic, usually
characterized by alternating infectious elementary body (EB)
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and noninfectious reticulate body (RB) stages. EBs infect ep-
ithelial cells and then differentiate into RBs within a host-
derived vacuole termed an “inclusion” (28). After RB multi-
plication by binary fission, RBs redifferentiate into EBs and
egress from infected epithelial cells to infect neighboring cells
(reviewed in reference 1). However, this developmental cycle is
disrupted under stressful growth conditions in vitro, such as
those imposed by gamma interferon (IFN-) (1, 10), antibiot-
ics (17, 23), nutrient deprivation, herpes simplex virus (HSV)
coinfection (57), and extracellular adenosine (37). Under these
conditions, bacteria survive by entering into a persistent mode
of growth that is typified by the formation of large, morpho-
logically aberrant RBs (ARBs) in which bacterial chromo-
somes continue to divide, but binary fission and differentiation
to EB are inhibited. Removal of the stress generally results in
reversal of these changes and differentiation into infectious
EBs (9).
The in vitro model of IFN--induced persistence and reac-
tivation of C. trachomatis has been particularly well studied (5,
6, 10). In human epithelial cells, IFN- induces the expression
of the enzyme indoleamine-2,3 dioxygenase (IDO1), which
catabolizes tryptophan to kynurenine (20, 53). Such depletion
interferes with the growth of C. trachomatis, which is a trypto-
phan auxotroph (14, 16). Continuous exposure to IFN- at
inhibitory concentrations results in the eradication of the in-
fection. However, exposure to subinhibitory IFN- concentra-
tions, which may be a likely scenario in vivo, results in the
development of persistent forms (6). The ability to develop
into a persistent form may be a key mechanism by which C.
trachomatis survives and establishes long-term infections in the
human host (21). Persistent forms may also be associated with
the pathology observed during chronic C. trachomatis infection
(6–8) and may underlie recurrent disease in the absence of
documented reinfection (18, 54). Hence, strategies to block
development of persistent forms and/or to eradicate estab-
lished persistent forms could likely benefit the host.
The IDO inhibitor 1-methyl-DL-tryptophan (1-MT) has pre-
viously been demonstrated to inhibit IDO-mediated trypto-
phan catabolism in C. pneumoniae-infected cells (33, 34).
Levo-methyl-tryptophan (L-1MT) is a specific IDO1 inhibitor
that can accumulate to steady-state levels in vivo that are suf-
ficient to inhibit this enzyme (51). Nontoxic IDO inhibitors,
similar to L-1MT, have already entered clinical trials as poten-
tial immunotherapeutic agents for the treatment of cancer
(http://clinicaltrials.gov/ct2/show/NCT00739609), because they
trigger antitumor immunity, partially by improving T-cell func-
tion (38), and act synergistically with conventional chemother-
apy (29). In this in vitro study, we investigated the effects of
L-1MT on C. trachomatis persistence. The results reported
here indicate that L-1MT blocks IFN--induced persistence of
C. trachomatis and reactivates C. trachomatis from established
persistent growth. Significantly, L-1MT limited the production
of infectious bacteria under each of the experimental condi-
tions and improved the efficacy of doxycycline in eradicating
persistent bacterial forms. In addition to providing a novel
mechanism to target IFN--induced doxycycline-resistant per-
sistent forms, L-1MT can be useful to further our understand-
ing of the IFN-–tryptophan–IDO1 axis, the ability of C. tra-
chomatis to persist, and its consequences to the host.
MATERIALS AND METHODS
C. trachomatis infections and cell culture conditions. HeLa 229 cells (hereaf-
ter, “HeLa cells”) were obtained from the ATCC and routinely propagated using
antibiotic-free complete RPMI 1640 (cRPMI) culture medium, consisting of
RPMI 1640 (Invitrogen) supplemented with 200 mM glutamine (Invitrogen),
0.25% (wt/vol) glucose (Sigma), and 10% fetal calf serum (Invitrogen). Human
AB serum (Sigma) was used in place of fetal calf serum (FCS) in performing the
described experiments (RP-10). Cells were seeded in 6- or 12-well culture plates
in RP-10 and cultivated for 24 to 36 h before infection. C. trachomatis serovar D
(D/UW-3/Cx) was used to infect HeLa cells at a multiplicity of infection (MOI)
of 2 in all experiments (15). Infections were performed by adding 1 ml/well of C.
trachomatis serovar D diluted in SPG (10 mM sodium phosphate [pH 7.2], 0.25
M glucose, 5 mM L-glutamic acid) to 6-well culture plates, which were centri-
fuged at 400  g for 40 min at 37°C. Immediately after infection, SPG was
removed and replaced with RP-10 alone, 10 ng/ml (200 U/ml) IFN- (Pepro-
tech), L-1MT (Sigma), or L-1MT plus 10 ng/ml IFN-. In some cases, 40 g/ml
tryptophan was added to cultures with L-1MT in the presence or absence of
IFN-. L-1MT was used at 0.05 to 1.0 mM, with the majority of experiments
conducted with 0.2 mM. The concentration used in this study was based on
preliminary titration experiments and published utilization of L-1MT in cancer
studies. The concentration of IFN- that was chosen induced persistent forms of
C. trachomatis, as defined by a noncultivable culture with small inclusions that
contained few, enlarged RBs and that could be reactivated within 24 h upon
removal of IFN- and replacement with fresh RP-10 (10). All cultures were
harvested at 38 h postinfection (hpi) unless otherwise stated. Trypsin-EDTA
solution (Invitrogen) was used to detach the cells from the culture plates, and
harvested cells were washed once with phosphate-buffered saline (PBS) before
proceeding to the appropriate experiments. For experiments in which recover-
able inclusion-forming units (IFU) were quantified, cell culture supernatants
were spun at 16,000  g to collect released EBs and cell lysates were prepared
by scraping cells from the culture plates. All pellets from culture supernatants
and cell lysates were resuspended in SPG and frozen at 80°C until ready to
titrate on fresh monolayers of HeLa cells. Before use, samples were thawed in a
37°C water bath and sonicated for 90 s. A fresh monolayer of confluent HeLa
cells was infected with 1:5 to 1:1,000 dilutions of cell lysates, and the recoverable
IFU/ml from each treatment were calculated as previously described (47).
qPCRs. For quantitative PCRs (qPCRs), cultured cells were collected, sus-
pended in RNA stabilization solution (RNAlater; Ambion), and stored at80°C
until used. Cell samples suspended in RNAlater were diluted with an equal
volume of PBS and centrifuged at 2,800  g for 20 min. The supernatants were
discarded and the isolation of total RNA from cell pellets was carried out using
the RNeasy minikit (Qiagen) following the manufacturer’s instructions. After
determination of the RNA concentration in each sample based on optical density
at 260 nm using a NanoDrop 1000 spectrophotometer (Thermo Scientific), 2 g
total RNA was reverse transcribed into cDNA. Random hexonucleotide primer
and Superscript III (Invitrogen) were used in the reverse transcription reaction.
qPCR for IDO1. Real-time quantitative PCR (qPCR) analysis was performed
on the ABI Prism 7500 system (Applied Biosystems) to semiquantitatively eval-
uate the gene expression of IDO1. A mixture containing sample cDNA (40 ng),
specific primer sets (4 pmol), and PCR premix (Power SYBR green PCR master
mix; Applied Biosystems) was added to each well in a 96-well plate. All PCRs
were carried out in triplicate. The expression of -actin was evaluated in each
sample for the normalization of total RNA levels among samples. The primer
sequences used were IDO1 (NM_002164) sense 5-AGA AGT GGG CTT TGC
TCT GC-3 and antisense 5-TGG CAA GAC CTT ACG GAC ATC TC-3 and
-actin (NM_001101.2) sense 5-CAT GTA CGT TGC TAT CCA GGC-3 and
antisense 5-CTC CTT AAT GTC ACG CAC GAT-3. The PCR cycle protocol
consisted of 50°C for 2 min (UDG incubation), 95°C for 2 min (denaturation),
and 45 cycles of 95°C for 15 s and 60°C for 60 s, followed by melting curve
analysis. The PCR product inserted into the pCRII-TOPO plasmid vector was
subcloned using a TOPO TA cloning kit (Invitrogen). Its nucleotide sequence
was confirmed using standard sequence analysis.
qPCR for chlamydial genes. For bacterial trancription analyses, primer/probe
sets were designed for the C. trachomatis euo, groEL1, trypB, omcB, and hctA
genes using Primer Express software (Applied Biosystems). -Actin quantifica-
tion was carried out using TaqMan -actin assay control reagents (Applied
Biosystems). Standard curves were generated using purified chromosomal tem-
plate DNA at concentrations ranging from 10 to 0.001 ng/well (data not shown).
Bacterial genome copy numbers were quantified (Universal PCR system; Ap-
plied Biosystems) using DNA preparations of a portion of each sample. Assays
were performed (One-Step RT-PCR master mix reagent; Applied Biosystems)
using RNA preparations from samples exposed to different culture conditions.
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Copy numbers were calculated and normalized to genome copy numbers (7500
sequence detector; ABI Prism). The primer/probe sets used are listed in Table 1.
Immunoblotting for IDO1. For immunoblot analyses of IDO1 expression,
mock-infected cells and C. trachomatis-infected cells were counted using a
Coulter counter (Beckman) and pelleted by centrifugation at 200  g. The cell
pellets were suspended in sample buffer (100 mM Tris, 10% [wt/vol] SDS, 10%
[vol/vol] glycerol, 5% [vol/vol] -mercaptoethanol, 1% bromophenol blue) at 5
104 cells/l. Cells were then lysed by ultrasonication for 10 short pulses. SDS-
PAGE and immunoblotting were performed using a standard protocol. IDO1
protein was visualized using 2 g/ml anti-IDO1 mouse primary monoclonal
antibody (Millipore) followed by an anti-mouse secondary antibody conjugated
to horseradish peroxidase (HRP). -Actin was used as a loading control using 40
ng/ml anti--actin polyclonal antibody (Abcam) followed by an anti-rabbit sec-
ondary antibody conjugated to HRP. The detection of immunoblots was per-
formed using a conventional chemiluminescence method as described earlier
(44).
Tryptophan and kynurenine measurement by reverse-phase HPLC. The levels
of tryptophan and kynurenine in cell culture supernatants were assessed at 8, 20,
and 38 h postinfection by reverse-phase high-performance liquid chromatogra-
phy (HPLC). To prepare samples for HPLC, a 200-l aliquot of each cell culture
supernatant was added to 800 l HPLC-grade methanol and vortexed to mix.
The mixture was incubated for 15 min at20°C and centrifuged at 16,300 g for
15 min at 4°C. The resulting supernatants were stored at 80°C until ready
to use.
The HPLC system consisted of a Dionex Ultimate 3000 (Sunnyvale, CA) with
a photodiode array UV detector. Chromatographic separation was achieved
using a 150- by 4.6-mm (inner diameter) C18 reverse-phase column (particle size,
3 m; ACCLAIM 120 C-18). For tryptophan measurement, the column was
equilibrated at a flow rate of 0.5 ml/min with 0.1 M sodium acetate buffer (pH
5.0) and then eluted with a linear gradient consisting of methanol (100%) and
acetonitrile (80%). For kynurenine determination, the column was eluted with a
linear gradient consisting of methanol (100%) and acetonitrile (80%). The ab-
sorbance of the column effluent was monitored at 280 and 365 nm for tryptophan
and kynurenine, respectively. The peaks of tryptophan or kynurenine were iden-
tified by comparison with the retention times of standard compounds (Sigma),
and quantification was based on the ratios of the peak areas of compound. The
limit of quantification for tryptophan and kynurenine is 0.2 M.
L-1MT toxicity study. Cellular toxicity of L-1MT was assessed by culturing
HeLa cells in medium alone or with 0.2 mM L-1MT or 1 mM L-1MT for 48 h.
As a positive control, a HeLa cell culture was exposed to 1 mM H2O2 for 2 h to
induce apoptosis or cell death. Following incubation of the HeLa cell cultures,
the culture supernatants were harvested and placed in 15-ml conical tubes.
Adherent cells were then washed with PBS, detached using 0.25% trypsin-EDTA
solution (Sigma), and neutralized by the addition of cRPMI. Detached cells were
then added to the corresponding culture supernatant, and the cells were centri-
fuged at 350  g at 10°C for 5 min to retrieve cell pellets. Staining using an
annexin V-fluorescein isothiocyanate (FITC) conjugate and propidium iodide
(PI) was performed following the manufacturer’s protocol (annexin V-FITC
detection kit; Calbiochem).
Immunofluorescent staining and deconvolution microscopy. HeLa cells were
cultivated on type 1 coverslips in 12-well plates for 24 to 36 h and then infected
with C. trachomatis as described. At 38 to 72 hpi, the cells were fixed with 4%
paraformadehyde and then permeabilized using 0.5% saponin (Sigma). To pre-
vent nonspecific staining, the cells were blocked with Background Sniper block-
ing reagent. (Biocare Medical). Meriflour anti-chlamydial lipopolysaccharide
(LPS) conjugated to fluorescein isothiocyanate (FITC) was used to stain C.
trachomatis. Nucleic acid was counterstained with DAPI (4,6-diamidino-2-phe-
nylindole) (Molecular Probes). Stained cells were mounted with Prolong Gold
antifade reagent (Invitrogen) and viewed under a fluorescence microscope. Im-
ages were acquired at 40 and 63 magnifications on an inverted Zeiss Axio-
Vision AX10 microscope with an AxioCam MR camera. Thirteen 200-nm Z-
sections were deconvolved using a constrained iterative Fourier transform with
30 to 40 iterations to obtain the final images. Point spread functions were
calculated as described previously (44).
Ultrastructural analyses. C. trachomatis-infected HeLa cells grown in RP-10
alone, RP-10 with 0.2 mM L-1MT, RP-10 with 10 ng/ml IFN-, or RP-10 with 10
ng/ml IFN- and 0.2 mM L-1MT were harvested at 38 hpi and 48 hpi. The cells
were pelleted by centrifugation (200  g) and washed twice by resuspension in
100 mM phosphate-buffered saline (PBS), pH 7.2. Cells were then fixed with
2.5% glutaraldehyde–2% parafomaldehyde and stored at 4°C until ready for use.
Fixed cells were processed for transmission electron microscopy, as previously
described (6). Electron micrographs were evaluated using ImageJ (2), as de-
scribed here. At least 10 separate micrographs were evaluated for each experi-
mental condition. After appropriately setting the scale, the freehand selection
tool was used to determine the cross-sectional area of each inclusion. Images
were thresholded prior to using the particle analysis function to enumerate the
number of EBs per cross-sectional inclusion area. For consistency, the same
threshold value (100) was used for all micrographs, and EBs were sized as
between 0.02 and 0.18 m2, with a circularity of 0.45 to 1.0. Heterogeneity in EB
size arises because not every EB within the cross-sectional area is within the same
plane. These values were chosen after tests using subtractive masking with
several images to ensure that no RBs were selected using these parameters.
Subtractive masking was also used to enumerate the number of RBs per inclu-
sion. Aberrant inclusions were independently counted by two individuals.
Doxycycline and L-1MT treatment and assessment of recoverable IFU. HeLa
cells were seeded in 12-well plates 24 h before infection. Cells were then infected
with serovar D and cultivated in RP-10 with 10 ng/ml IFN- for 38 h to induce
persistence. In the initial experiments, persistent cultures were exposed to doxy-
cycline concentrations ranging from 0.05 to 50 g/ml. In these experiments, it
was observed that exposure to doxcycline concentrations above 20 g/ml for 48 h
was toxic to HeLa cells, consistent with previous observations with other mam-
malian cell lines (19, 41). Doxycycline, at a concentration of 1 g/ml, was used
alone or in combination with 0.2 mM L-1MT in the experiments reported here.
To assess the recoverable IFU, treated cells were reactivated by replacing the
medium with RP-10 with 40 g/ml tryptophan and 1 g/ml cycloheximide for
48 h. Culture media in C. trachomatis-infected HeLa cell cultures were replaced
with SPG, and the cells were scraped from the culture plates. The cell scrapings
were frozen at 80°C until ready to use, and the number of recoverable IFU was
determined as described earlier.
Statistical analyses. Statistical analyses were based on data from three to five
experiments. Student’s t test (50) was utilized to determine differences between
control and experimental conditions.
RESULTS
IFN- induces IDO1 expression in HeLa 229 cells. Exposure
of HeLa cells to IFN- is well documented to induce IDO1
expression (53). Therefore, HeLa cells were exposed to 10
ng/ml IFN- and the level of IDO1 induction in C. trachomatis
serovar D infection was assessed. Under these conditions, in-
fection rates of 40 to 50% were detected at 38 hpi; pertinently,
cycloheximide, an inhibitor of translation routinely used to
prevent the proliferation of mammalian cells, was not added to
the HeLa cultures in these experiments to prevent inhibition of
IDO1 expression (5). IDO1 mRNA expression was first deter-
mined in C. trachomatis-infected HeLa cells and matched
mock-infected control cultures cultivated under different con-




Forward primer Reverse primer Probe
euo ATCTGTCTACTTCCGAAACGTGAA CGCATTGGTGCTATGAAAGGA CCCAAGCAGATCCCCGACGCT
groEL1 AGGACGGCCGGATTCAG AAGACGCTTTGGTTCTAATCTACGA TGTAAAACAGGAAGGAAATCTTTGATCCCAGAA
trpB CACTCCATTTCCGCTGGA GCTCGTCCTGACTCATGCATT CTTCAGTTGGGCCAGATCATGCCG
omcB CTCTAACACCCCGCTAGCAAA TCATCAGACGAGCAGTGACGAT AACTCGCCACACTAGTCACCGCGAA
hctA CTTTACGATATACCTTCGCGATCTT GTATCCAACAAAATTTGCTTAAAGCA ACTCTTTGTGCTGCGGCTTTATTTCCTTTTT
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ditions using quantitative real-time PCR. We observed that 10
ng/ml of IFN- induced IDO1 mRNA by approximately 30-
fold in uninfected HeLa cells (Fig. 1A). Strikingly, induction
was significantly more pronounced (70-fold) in C. trachoma-
tis-infected HeLa cells that were treated with IFN- (P 
0.001). The increased induction did not result from C. tracho-
matis infection alone because IDO1 induction was not ob-
served in those C. trachomatis-infected cells not exposed to
IFN-. As anticipated, the IDO1 inhibitor L-1MT (0.2 mM)
did not affect IDO1 mRNA expression in either mock- or C.
trachomatis-infected cells exposed to IFN- (data not shown).
The levels of IDO1 mRNA were corroborated with IDO1
protein levels using immunoblot analysis (Fig. 1B). Consistent
with the mRNA analysis, exposure to IFN- resulted in detect-
able levels of IDO1 protein in mock-infected HeLa cells, with
higher levels of expression observed when C. trachomatis-in-
fected cells were exposed to IFN-. Together these observa-
tions indicate that C. trachomatis infection of HeLa cells po-
tentiates IDO1 induction by IFN-. While not detected by our
immunoblot, we note that it is likely that HeLa cells not ex-
posed to IFN- express low baseline levels of IDO1 protein.
This is because addition of L-1MT to control HeLa cells re-
sulted in a small increase in tryptophan levels as measured by
HPLC (Fig. 2A) (data not shown).
IDO1-mediated tryptophan catabolism is inhibited at 20 h
postinfection by the addition of L-1MT. IDO catabolizes tryp-
tophan via the kynurenine pathway (46, 53). Therefore, tryp-
tophan and kynurenine levels in cell culture supernatants can
be used to determine the induction of IDO1 activity by IFN-.
We examined tryptophan and kyurenine levels in mock-in-
fected and C. trachomatis-infected HeLa cells under the fol-
lowing conditions: (i) in medium alone, (ii) with addition of 0.2
mM L-1MT, (iii) with addition of 10 ng/ml IFN-, or (iv) with
addition of both 10 ng/ml IFN- and 0.2 mM L-1MT. Because
one developmental cycle of C. trachomatis serovar D is typi-
cally completed in 48 h, tryptophan catabolism was measured
in culture supernatants at early (8 hpi), middle (20 hpi), and
mid-late (38 hpi) stages of chlamydial development. No signif-
icant difference in tryptophan levels was observed between the
different culture conditions at 8 hpi (data not shown). At 20
hpi, tryptophan fell below the level of detection (0.2 M) in
cell cultures exposed to IFN- alone, but not in 0.2 mM
L-1MT-supplemented IFN--exposed cultures (Fig. 2A).
These results indicate that L-1MT inhibited IFN--induced
IDO1 activity at the mid-stage (20 hpi) of C. trachomatis de-
velopment. At 38 hpi, tryptophan levels in all culture superna-
tants from IFN--exposed HeLa cells were below the 0.2 M
detection limit, in contrast to C. trachomatis-infected cells
treated with IFN- plus L-1MT, which retained 0.26 M tryp-
tophan. This suggests that 	99% of tryptophan in the culture
media was either utilized or catabolized in all cultures exposed
to IFN- at this later stage of C. trachomatis development (Fig.
2B). Furthermore, at 20 and 38 hpi, kynurenine was produced
in all HeLa cell cultures that were exposed to 10 ng/ml IFN-
(Fig. 2C and D). Because it was confirmed that kynurenine was
absent in unused culture media under the four conditions
evaluated, its presence in culture supernatants indicates that
IFN--induced IDO1 activity resulted in kynurenine produc-
tion, as reported previously (32, 52, 58). We also noted that
significant differences in kynurenine production could only be
observed after a shorter period (20 hpi) of IFN- exposure, at
which time kynurenine is unlikely to have been catabolized
into downstream metabolites.
L-1MT has no toxic effects on HeLa 229 cells and does not
inhibit C. trachomatis growth. To assess the toxicity of L-1MT
on host cells, HeLa cell cultures were exposed to 0.2 mM or 1
mM L-1MT for 48 h and assessed for apoptosis or necrosis by
double staining using annexin V and propidium iodide (PI).
Flow cytometric analyses demonstrated that exposure of HeLa
cells to 0.2 mM and 1 mM L-1MT (i.e., five times more than
the dosage used in this study) allowed the recovery of 95%
viable cells, which is comparable to the untreated negative
control (Fig. 3). In contrast, HeLa cells exposed to 1 mM H2O2
displayed both apoptosis and necrosis (Fig. 3).
We also demonstrated that L-1MT alone does not alter the
normal development of C. trachomatis, as shown by the similar
ultrastructural morphology of the inclusions formed in the
presence of 0.2 mM L-1MT and the untreated control (Fig.
4A). In addition, neither 0.2 mM nor 1 mM L-1MT decreased
recoverable IFU from C. trachomatis-infected cells at 48 hpi
(Fig. 4B).
L-1MT blocks IFN--induced C. trachomatis persistence.
IFN- can induce C. trachomatis to enter into a persistent
mode of growth (40). Inclusions formed during IFN--medi-
FIG. 1. IDO1 expression in IFN--treated and C. trachomatis-in-
fected HeLa 229 cells. Cells were mock infected by centrifugation with
SPG alone or infected with C. trachomatis serovar D and cultivated in
the absence or presence of 10 ng/ml IFN- for 38 h. Infection was
performed in the absence of cycloheximide, at an MOI of 2, to achieve
40 to 50% infection at 38 hpi. (A) HeLa cell IDO1 mRNA expression
at 38 hpi was assessed by real-time PCR. IDO1 expression was nor-
malized to -actin, and results are presented as fold induction relative
to control (uninfected, no IFN-) HeLa cells. The data presented are
the means and standard deviations from 3 separate experiments. The
asterisks indicate that IDO1 was induced to a significantly higher level
by IFN- exposure of C. trachomatis-infected HeLa cells relative to
uninfected cells (P  0.001). (B) Representative immunoblot of HeLa
cell lysates probed with an anti-IDO1 monoclonal antibody. IDO1
migrated at 42 kDa relative to molecular mass standards. -Actin
was used as a loading control, and all proteins migrated with molecular
masses similar to those predicted.
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ated persistence are small and contain aberrant RBs (ARBs)
that display a distinct gene expression profile. IFN--induced
IDO expression has been demonstrated to restrict C. tracho-
matis growth, which is attributed to tryptophan depletion be-
cause it is reversed by addition of tryptophan. In the experi-
ments described below, the temporal inhibition of IDO1
activity by 0.2 mM L-1MT was observed to block IFN--in-
duced C. trachomatis persistence. We assessed the capacity of
0.2 mM L-1MT to inhibit the effects of IFN- using quantita-
tive analyses of inclusion images obtained by electron micros-
copy and through gene expression studies.
To determine the effect of L-1MT on C. trachomatis growth
at the ultrastructural level, a morphological assessment of C.
trachomatis inclusions formed under different growth condi-
tions was performed at 48 hpi and quantitatively evaluated
using ImageJ software (Table 2). The mean inclusion cross-
sectional area of control cultures was 120.9 m2, with a mean
of 146 EBs per inclusion (Fig. 5A to C). This is characteristic
FIG. 2. Partial inhibition of IDO1-mediated tryptophan catabolism to kynurenine by L-1MT during C. trachomatis infection of HeLa 229 cells.
Tryptophan and kynurenine concentrations in culture supernatants. (A) Tryptophan at 20 hpi; (B) tryptophan at 38 hpi; (C) kynurenine at 20 hpi;
(D) kynurenine at 38 hpi. Concentrations of tryptophan and kynurenine were measured by reverse-phase HPLC at 20 and 38 hpi in cell culture
supernatants from mock-infected and C. trachomatis-infected HeLa cells cultivated in the presence and absence of 10 ng/ml IFN-, 0.2 mM L-1MT,
or both. The data presented are the means and standard deviations from 3 separate experiments.
FIG. 3. Flow cytometric analyses of L-1MT toxicity on HeLa 229 cells. Double staining using FITC-conjugated annexin V and propidium iodide
was used to profile control HeLa cells or cells exposed to 0.2 mM or 1.0 mM L-1MT. The levels of apoptosis or necrosis detected under these
conditions did not differ from control conditions. Treatment with 1.0 mM H2O2 was used as a positive control to confirm that the reagents detected
apoptotic and necrotic cells.
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of normal development. Treatment with IFN- (Fig. 5D to F)
significantly decreased the average cross-sectional area of in-
clusions to 18.8 m2 (P 0.0001), with a mean of less than one
EB, and eight aberrant RBs per inclusion. Relative to treat-
ment with IFN- alone, exposure to both IFN- and L-1MT
(Fig. 4G to I) significantly increased the average inclusion area
to 46.7 m2, decreased the mean number of aberrant forms to
less than one per inclusion (P 0.0001), and increased average
EB numbers to 13/inclusion (P  0.0001). To evaluate the
possibility that there were condition-specific differences in the
number of EBs and RBs per inclusion, alterations in inclusion
size and the numbers of EBs, RBs, and aberrant forms per
cross-sectional area were also calculated (Table 3). The results
of these analyses corroborate the pattern of findings presented
in Table 2 and eliminate the possibility that decreased numbers
of EBs and RBs resulted from a proportional decrease in the
size of the inclusion. Thus, ultrastructural analyses indicate
that addition of L-1MT to C. trachomatis-infected cells induced
the formation of inclusions with unique morphological charac-
teristics that are distinct from persistent inclusions.
To further confirm at the molecular level whether L-1MT
treatment blocks the induction of persistence, we performed
gene expression analyses of two early chlamydial genes (euo
and groEL) and two late chlamydial genes (omcB and hctA). A
comparison of the gene expression pattern of C. trachomatis
grown in L-1MT-treated-culture with that of persistent forms
relative to the normal growth control is shown in Fig. 6. Con-
sistent with previous data (6, 10), euo expression and groEL
expression were upregulated during IFN--induced persis-
tence compared to normal infection (Fig. 6). euo and groEL
genes are typically expressed early during chlamydial develop-
ment. Because we did not observe an upregulation of euo or
groEL in the culture treated with L-1MT, this indicates that
these genes are differentially regulated in IFN--induced per-
sistence and IFN-–L-1MT exposure. This finding is supported
by the observation that in contrast to persistent C. trachomatis
cultures, infected cultures grown under conditions that in-
cluded L-1MT upregulated the late genes omcB and hctA.
These genes encode structural and regulatory proteins re-
quired for the transition of RBs back into EBs (10, 45). These
data demonstrate that unlike persistent growth, C. trachomatis
development under conditions with L-1MT allows for normal
RB transformation to EBs. Based on the expression of selected
early and late genes, the C. trachomatis growth pattern exhib-
ited in the presence of both IFN- and L-1MT is distinct from
C. trachomatis persistence, displayed in the presence of IFN-
alone. Together, these data indicate that the L-1MT treatment
could block the induction of C. trachomatis persistence by
IFN-. Intriguingly, exposure to L-1MT resulted in a unique
development pattern, as indicated both by ultrastructural stud-
ies and by gene expression analyses.
L-1MT treatment results in the limited replication of C.
trachomatis. Preliminary studies indicated that L-1MT addition
to IFN--treated cells did not reduce the number of C. tracho-
matis inclusions formed at 38 hpi (data not shown). This is
consistent with a study by Pantoja et al. with the C. pneumoniae
infection model using 1MT, which is a mix of both L-1MT and
dextro-1-methyl tryptophan (D-1MT). The distinct growth pat-
tern of bacteria formed in IFN-–L-1MT-exposed cultures
prompted us to further evaluate the effect of adding L-1MT to
IFN--exposed-cells on chlamydial development. This was
achieved by assessing IFUs that could be recovered from cell
lysates and cell culture supernatants at 38, 48, and 72 hpi
(Fig. 7).
Characteristic of normal development, the IFU in cell ly-
sates and culture supernatants from control cultures and cul-
tures exposed to L-1MT alone increased over the course of 72
FIG. 4. L-1MT does not affect the normal developmental cycle of C. trachomatis. The developmental growth of C. trachomatis in the absence
or presence of 0.2 mM L-1MT was evaluated by ultrastructural analyses (A) and IFU recovery (B). Infected cells were harvested at 38 hpi for the
ultrastructural comparison between untreated control and 0.2 mM L-1MT-treated infected cells. IFU were quantified as previously described from
cells scraped at 48 hpi.
TABLE 2. Partial reversion by L-1MT of the effect of IFN- on








 40c 146 
 82c 33.2 
 18.2c 0.1 
 0.3c
IFN- 18.8 
 8.6 0.5 
 0.8 0.5 
 0.8 7.6 
 3.1
IFN-, L-1MT 46.7 
 27.9d 13.4 
 8.3d 8.6 
 6.3d 0.9 
 1.4d
a Values represent the mean 
 standard deviation inclusion cross-sectional
area in 10 randomly selected electron micrographs (EMs).
b Values represent the mean 
 standard deviation numbers of elementary
bodies (EBs), reticulate bodies (RBs), and aberrant reticulate bodies (ARBs)
observed in 10 randomly selected EMs. EBs were counted using ImageJ as
described in Materials and Methods. The distinction between RBs and ARBs
was scored independently by two individuals.
c Values under control conditions were determined to be significantly different
from the other conditions using Student’s t test (P  0.0001).
d Values observed in the presence of IFN- and L-1MT were significantly
different from those observed in the presence of IFN- alone (Student’s t test,
P  0.0001).
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hpi (Fig. 7A). Consistent with the persistent growth of bacteria,
cell lysates and culture supernatants from C. trachomatis-in-
fected HeLa cultures exposed to IFN- alone did not yield
detectable IFU up to 48 hpi and yielded significantly lower IFU
at 72 hpi compared to all other culture conditions. In IFN-–
L-1MT-exposed C. trachomatis-infected HeLa cell cultures, we
observed limited IFU from cell lysates and cell culture super-
natants collected at 48 hpi, and this further decreased signifi-
cantly at 72 hpi (Fig. 7A). Furthermore, in contrast to the
control, immunofluorescent staining for chlamydia in IFN-–
L-1MT-exposed cultures revealed little evidence of secondary
infections at 72 hpi (Fig. 7B). We also did not observe evidence
of persistent forms of C. trachomatis in IFN-–L-1MT-exposed
cultures (Fig. 7B).
Together these data indicate that addition of L-1MT to
IFN--treated cultures blocked the induction of persistence;
interestingly, this occurs via a mechanism that severely restricts
recoverable IFU.
Further support that L-1MT limits the productive multipli-
cation of C. trachomatis exposed to IFN- was obtained from
data demonstrating that the ratio of chlamydia to host DNA
was not significantly increased by the addition of L-1MT (Fig.
8). In contrast, addition of tryptophan to IFN-–L-1MT-ex-
posed cells resulted in more than a log-fold increase in the
relative chlamydial genome copy number (Fig. 8). These data
suggest that unlike tryptophan, which has been demonstrated
FIG. 5. Treatment with L-1MT results in a unique morphological characteristic of C. trachomatis inclusions. Electron micrographs of 3
representative inclusions from C. trachomatis grown in medium alone (control) (A to C), medium with 10 ng/ml IFN- (D to F), and medium with
10 ng/ml IFN- together with 0.2 mM L-1MT (G to I). The scale bars represent 0.5 m. The cells were harvested at 48 hpi and processed for
transmission electron microscopy. Inclusions that were formed in culture with 10 ng/ml IFN- plus 0.2 mM L-1MT formed significantly less EBs
and RBs than those that were grown in medium alone.
FIG. 6. C. trachomatis cultures that were exposed to IFN- exhib-
ited a unique gene expression pattern with the addition of 0.2 mM
L-1MT. Data are expressed as fold change compared to the no-IFN-
control (medium alone), which was designated a value of 1 (horizontal
line). White bars represent gene expression of persistent forms grown
in the presence of 10 ng/ml IFN-, and gray bars represent gene
expression of C. trachomatis in cultures treated with 10 ng/ml IFN-
and 0.2 mM L-1MT. Statistical significance of the difference in gene
expression levels between persistent (IFN-) and IFN-- and
L-1MT-treated C. trachomatis were evaluated using Student’s t test.
Comparisons of gene expressions between the two conditions reveal
significant differences in the expression level of the indicated gene. *,
P  0.05; **, P  0.01.
TABLE 3. The reduced number of EBs/m2 of inclusion area





 0.45 0.29 
 0.14 0.001 
 0.002
IFN- 0.03 
 0.06 0.02 
 0.03 0.412 
 0.412
IFN-, L-1MT 0.33 
 0.17 0.21 
 0.16 0.034 
 0.059
a The values shown represent means 
 standard deviations from the same 10
samples analyzed in Table 1.
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to induce the reactivation of C. trachomatis from persistent
forms to normal productive development, L-1MT does not
support the productive multiplication of the bacterium.
Effects of exogenous tryptophan on IFN-–L-1MT-exposed
C. trachomatis-infected HeLa cells. To further investigate the
effects of the addition of exogenous tryptophan on C. tracho-
matis-infected L-1MT-treated HeLa cells, qPCR was used to
quantify trpB gene expression in cultures with L-1MT or
L-1MT supplemented with tryptophan, in the absence or pres-
ence of IFN-. Our results indicate that the addition of L-1MT
to IFN--exposed cells decreased trpB gene expression com-
pared to IFN- alone (Fig. 9). However, infected cultures
treated with IFN- and L-1MT maintained elevated trpB ex-
pression compared to untreated (no-IFN-) control cultures,
indicating that L-1MT by itself does not inhibit trpB expres-
sion. We interpret this finding to indicate that even during
L-1MT exposure, C. trachomatis continues to respond to tryp-
tophan depletion in the host cell (3, 59). Consistent with this
interpretation, a striking decrease in trpB expression was ob-
served when tryptophan was added to cultures treated with
IFN- and L-1MT. Therefore, exogenous tryptophan can re-
press the trpB gene expression in the presence of L-1MT (Fig.
9), indicating that L-1MT likely does not interfere with tryp-
tophan transport into the chlamydial inclusion.
Next, we examined whether the addition of tryptophan
raised the recoverable IFU in IFN--exposed cells in the pres-
ence of L-1MT. Here we found that the addition of tryptophan
not only rescued the persistent growth phenotype, but it could
also countermand the decrease in recoverable IFU that results
from exposure to L-1MT (Fig. 10). These data in conjunction
with our other findings reveal that L-1MT’s effect on chlamyd-
ial growth primarily arises from its ability to modulate trypto-
phan levels in cells infected by C. trachomatis and consequently
to the bacterium.
FIG. 7. L-1MT limits the recovery of infectious elementary bodies from IFN--treated C. trachomatis-infected cell cultures. (A) IFU counts
from C. trachomatis-infected HeLa cells cultivated in (i) medium alone (control), (ii) medium supplemented with 0.2 mM L-1MT, (iii) medium
supplemented with 10 ng/ml IFN-, or (iv) medium supplemented with both 10 ng/ml IFN- and 0.2 mM L-1MT. IFU were measured at 38, 48,
and 72 hpi. At each time interval, culture supernatants were spun at 16,000  g and resuspended in SPG. Monolayers of infected HeLa cells were
scraped with SPG. Both supernatants and cell lysates were frozen and sonicated before titration on fresh HeLa cells to determine IFU/ml. (B) C.
trachomatis growth pattern at 72 hpi. Direct immunofluorescence images were obtained by staining cells fixed on coverslips at 72 hpi using
anti-chlamydial LPS conjugated to FITC. Nuclei were counterstained with DAPI.
FIG. 8. L-1MT does not alleviate the decrease in chlamydial ge-
nome copy numbers in IFN--exposed cultures. Mock-infected and C.
trachomatis-infected cells were exposed to 0.2 mM L-1MT or 0.2 mM
L-1MT supplemented with 40 g/ml tryptophan in the presence or
absence of IFN- for 38 h. Chlamydial genome copy number was
quantified by qPCR and normalized to host genome. Here we show
that the addition of L-1MT did not significantly increase the chlamyd-
ial genome copy number, but addition of exogenous tryptophan was
able to increase chlamydial multiplication in the presence of 10 ng/ml
IFN- and 0.2 mM L-1MT.
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L-1MT treatment can reactivate C. trachomatis from an es-
tablished persistent growth mode. C. trachomatis that have
entered into an IFN--induced persistent mode of growth can
be reactivated by removing IFN- and adding exogenous tryp-
tophan. Therefore, the ability of L-1MT to reactivate an es-
tablished persistent C. trachomatis infection was examined. For
these investigations, 0.2 mM L-1MT was added to IFN--
treated cultures at 38 hpi, after persistent forms had devel-
oped. Ultrastructural analyses clearly indicated that L-1MT
could reactivate C. trachomatis from a persistent mode of
growth (Fig. 11A). A change in the morphology of persistent
chlamydial forms was observed as early as 24 h post-L-1MT
treatment (Fig. 11A2), and redifferentiation into EBs was ob-
served at 48 h post-L-1MT treatment (Fig. 11A3). However, in
contrast to cultures exposed to IFN- alone, the number of
inclusions in persistent C. trachomatis cultures reactivated with
L-1MT decreased significantly over time. Quantitation re-
vealed significantly fewer inclusions at 48 h post-L-1MT treat-
ment compared to 24 h post-L-1MT treatment (P 0.01) (Fig.
11B). These data indicate that unlike the outcome of conven-
tional reactivation of persistent C. trachomatis by IFN- re-
moval and/or tryptophan replenishment, reactivation by add-
ing L-1MT severely restricts bacterial multiplication.
Treatment with L-1MT sensitizes persistent C. trachomatis
to doxycycline. In a recent study by Reveneau and coworkers,
IFN--induced persistent forms of C. trachomatis were more
refractory to doxycycline exposure than those that underwent
normal development (39). As doxycycline is one of the two
antibiotics used most often to treat C. trachomatis infection, we
examined the effect of L-1MT on doxycycline resistance of
persistent forms of C. trachomatis. Because L-1MT can reac-
tivate C. trachomatis from persistent growth to a limited extent,
we tested whether combining L-1MT with doxycycline was
more effective at eradicating IFN--induced persistent forms
of C. trachomatis than doxycycline alone.
The experimental protocol depicted in Fig. 12A was used to
determine the number of recoverable IFU when IFN--treated
cultures were also exposed to L-1MT alone, doxycycline alone,
or doxycycline plus L-1MT. Briefly, IFN- was added at the
time of infection to induce persistence. At 38 hpi, persistent
cultures were treated with doxycycline, L-1MT, or both for an
additional 24 h. Following this, IFN-, doxcycline, and L-1MT
were substituted for by culture medium supplemented with
tryptophan and cycloheximide for 48 h, after which recoverable
IFU were measured.
Recoverable IFU were decreased by approximately 4-fold by
exposure to 0.2 mM L-1MT alone and 9-fold by exposure to 1
g/ml doxycycline alone, compared to untreated cultures (Fig.
12B). Strikingly, treatment with 0.2 mM L-1MT combined with
1 g/ml doxycycline reduced recoverable IFU to a level below
the assay’s detection limit. Indeed, this combination was more
effective at reducing recoverable IFU than using doxycycline
alone, even at concentrations as high as 10 g/ml (data not
shown). Therefore, these data indicate that the combination
L-1MT and doxycycline is more effective at clearing persistent
forms of C. trachomatis than doxycycline alone.
DISCUSSION
Problems associated with persistent chlamydial growth in-
clude the possibilities that it (i) permits immune evasion (6),
(ii) provides a reservoir of bacteria that can be reactivated
when conditions in the infected microenvironment are permis-
sive (9, 10), and (iii) may underlie the recalcitrance of chla-
mydiae to some commonly used antibiotics (11, 12, 39, 60). In
this study, we explored the effects of the specific IDO1 inhib-
FIG. 9. Addition of exogenous tryptophan reduced trpB gene ex-
pression in IFN-- and L-1MT-exposed C. trachomatis-infected HeLa
cells. Mock-infected and C. trachomatis-infected HeLa cells were ex-
posed to 0.2 mM L-1MT or 0.2 mM L-1MT and 40 g/ml tryptophan
in the presence or absence of 10 ng/ml IFN-. The expression of the
trypB gene was quantified and is normalized to chlamydial genome
copy number. An elevated level of trpB was observed in cultures ex-
posed to IFN- alone. Although still elevated compared to the level in
the no-IFN- controls, a 4-fold decrease in trpB was observed in cell
cultures exposed to IFN- plus L-1MT compared to IFN- alone.
Addition of 40 g/ml exogenous tryptophan decreased trypB expres-
sion to a level comparable to that in the no-IFN- controls.
FIG. 10. Addition of tryptophan can alleviate the limited IFU re-
covery in C. trachomatis-infected cultures exposed to IFN- and
L-1MT. C. trachomatis-infected HeLa cells were cultured in the pres-
ence or absence of IFN- with 0.2 mM L-1MT or 0.2 mM L-1MT with
40 g/ml exogenous tryptophan. Infected HeLa cells were scraped,
frozen, thawed, and sonicated to determine the number of recoverable
IFU. The decrease in IFU observed in the presence of IFN- was not
completely alleviated by the addition of L-1MT alone, but was in-
creased significantly with the addition of exogenous tryptophan, even
in the presence of L-1MT.
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itor L-1MT on the growth and development of C. trachomatis
in HeLa cells. Our results indicate that 0.2 mM L-1MT can (i)
block IFN--mediated C. trachomatis persistence, (ii) limit the
formation of infectious EBs, and (iii) increase the susceptibility
of persistent C. trachomatis forms to doxycycline treatment.
We hypothesize that the mechanism underlying the ability of
L-1MT to rescue C. trachomatis from IFN--mediated persis-
tence, while limiting the productive multiplication of the bac-
terium, involves the temporal depletion of tryptophan (Table
4). We infer that because L-1MT prevented tryptophan deple-
tion at the mid-stage of chlamydial development (20 hpi), C.
trachomatis bypassed IFN--induced persistence. However, by
permitting depletion of tryptophan at the mid-late stage of the
chlamydial development (38 hpi), the available tryptophan was
insufficient to support normal late-stage development of bac-
teria. Thus, as a consequence of the addition of L-1MT to
IFN--exposed C. trachomatis, a unique chlamydial growth
pattern was observed that is distinct from persistent forms and
also characterized by a limited productive release of infectious
EBs (Fig. 13). Although L-1MT is considered a stable mole-
cule (56, 61), its half-life under the conditions we have used is
unknown. Therefore, it is also possible that the reduced de-
pletion of tryptophan at 38 hpi resulted from a decreased
inhibition of IDO1 at that time.
Reveneau and coworkers reported that doxycycline, a first-
line antibiotic commonly used to treat C. trachomatis infec-
tions, was more effective in clearing normal replicating C.
trachomatis infections in vitro than those that were cultivated in
the presence of IFN-. Their observations permitted them to
conclude that IFN--induced persistent forms of C. trachoma-
tis were more resistant to this antibiotic (39). Although L-1MT
blocked persistence, it also severely restricted bacterial multi-
plication. Therefore, we investigated whether using L-1MT in
combination with doxycycline was more effective against per-
sistent bacteria than doxycycline alone. Our data indicate that
L-1MT reactivated persistent C. trachomatis ineffectually, re-
sulting in a sharp decrease in the number of EBs observed
ultrastructurally and IFUs measured biologically. This ineffec-
tual reactivation resulted in an increased susceptibility to doxy-
cycline. Although as yet unexplored, we propose that the in-
creased sensitivity to doxycycline in the presence of L-1MT
results from the molecular mechanism by which doxycycline
functions—that is blockade of protein synthesis by binding the
ribosome acceptor site and therefore inhibiting the association
of aminoacyl-tRNA with the mRNA-ribosome complex. It is
known that tryptophan deprivation severely decreases protein
synthesis in persistent C. trachomatis forms without completely
blocking genome replication (31). Therefore, even a limited
alleviation of tryptophan deprivation likely provides molecular
targets for doxycycline by restoring protein synthesis to some
measure. Our finding that a combination of L-1MT and doxy-
cycline is superior to the use of doxycycline alone is similar to
previous suggestions that combination drug treatment of C.
trachomatis can be superior to therapy with a single antibiotic
(49).
Currently, there is no direct and indisputable evidence that
FIG. 11. L-1MT can reactivate C. trachomatis from persistence but results in a decrease in the number of inclusions. (A1) Electron photomi-
crograph of inclusion at 38 hpi with IFN-: the inclusion has few large aberrant reticulate bodies (ARB) typical of C. trachomatis persistence. (A2)
24 h after L-1MT treatment of a persistent C. trachomatis culture, reticulate bodies (RB) start to form. (A3) 48 h after L-1MT treatment of a
persistent C. trachomatis culture, few small and dense elementary bodies (EB) are formed. The scale bars are equivalent to 0.5 m. (B) Inclusion
counts of C. trachomatis-infected cultures after addition of IFN- or L-1MT with IFN- at 24 hpi (gray bar) and at 48 hpi (black bar). Over time,
there was no significant decrease in the number of inclusions in cells treated with IFN- alone. Although L-1MT can reactivate C. trachomatis from
the persistent growth mode, the number of inclusions decreased over time in cultures treated with L-1MT (**, P  0.01). Data were pooled from
3 independent experiments.
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persistence occurs in vivo due to the challenging nature of
these studies. However, multiple indications from morpholog-
ical (12), clinical (18, 35), and physiological (4) studies support
the in vivo occurrence of a C. trachomatis persistent state. If
IFN--mediated persistent forms of chlamydiae exist in vivo, a
potential therapeutic complication would be the apparent rel-
ative resistance of this growth form to doxycycline treatment
(39). There are reports of recurrent infections in women who
have been previously treated with doxycycline (11, 18). While
the majority of recurrent infections likely result from reinfec-
tion, it remains possible that some arise from reactivation of
small reservoirs of persistent bacteria that have not been fully
eliminated by antibiotics. This possibility is supported by the
study of Dean et al., who observed multiple, same-serovar
recurrent C. trachomatis infections in women over a 2- to
5-year period despite antibiotic treatment (18). Since the most
serious ramifications of C. trachomatis infections to human
health are primarily associated with chronic or repeated infec-
tions, the observation by Reveneau and coworkers that IFN-
-induced persistent forms of C. trachomatis are relatively re-
sistant to doxycycline may have serious repercussions.
The implication of IFN--mediated persistence in vivo has
been elegantly discussed by others (7, 27), and consequently,
the use of tryptophan supplementation in combination with
antibiotics as a therapeutic approach has previously been pro-
posed (48). The data presented here imply this approach would
not be effective in clearing C. trachomatis infection in vivo;
indeed, it may be detrimental to disease outcome because
reactivation of persistent bacterial forms through tryptophan
supplementation would restore efficient production of elemen-
tary bodies. Furthermore, based on reports by others (15, 27),
we believe that tryptophan supplementation may naturally oc-
cur in vivo when coinfecting microorganisms like Trichomonas
vaginalis could provide an indole source that might be utilized
by genital serovars of C. trachomatis to synthesize tryptophan.
This phenomenon has been postulated to be detrimental in
controlling chronic C. trachomatis infections as it may reacti-
vate IFN--induced persistent bacterial forms that could act as
bacterial reservoirs (15, 27, 39). In contrast to tryptophan sup-
plementation, treatment of persistent forms with L-1MT re-
sults in a restricted return to the normal development cycle,
with limited production of EBs. Consequently, L-1MT-treated
persistent forms are more sensitive to doxycycline treatment.
We hypothesize that this combination approach might be more
efficacious for treatment as it would decrease the probability of
escape of persistent forms from the effects of doxycycline
alone. For these reasons, we propose L-1MT would be a novel
and effective approach to experimentally explore, and interfere
with, the survival and the long-term association of C. tracho-
matis with its human host.
We believe that our findings provide sufficient proof of prin-
ciple to warrant further investigation of the efficacy of L-1MT
in human in vitro models and nonhuman primate models of C.
trachomatis infection. If the biological half-life of L-1MT at
mucosal sites is found to reduce its availability in C. trachoma-
tis-infected cells, we note that L-1MT can be administered
several times per day, as reported for animal models that
explore its use as a therapeutic against cancer (56, 61). Should
our findings translate to improved in vivo clearance of C. tra-
chomatis in nonhuman primate models, it would indicate that
partial rescue of auxotropy in combination with therapy that
targets replication is a potent mechanism to clear infection by
a pathogen. Indeed, we note that auxotrophy is not unusual
among intracellular pathogens, where evolution has often
driven the loss of a pathogen’s capacity to synthesize metabo-
lites readily available from the host. For example, the intracel-
lular protozoan parasite Leishmania is a tryptophan auxotroph
(24), which frequently escapes therapeutic surveillance com-
TABLE 4. Temporal depletion of tryptophan by addition of L-1MT








8 (early) 26 
 1.4 25 
 2.1 20 
 0.7 25 
 0.7
20 (mid) 10 
 1.9 15 
 6.6 0 17 
 9.0
38 (mid-late) 3 
 1.9 7 
 3.4 0 0
a Represented by the red path in Fig. 13 (normal development).
b Represented by the blue path in Fig. 13 (induction of persistence).
c Represented by the green path in Fig. 13 (combined IFN-–L-1MT expo-
sure).
FIG. 12. L-1MT improves the efficacy of doxycycline in clearing
persistent C. trachomatis infection in HeLa cells. (A) Schematic dia-
gram of the experiment. A monolayer of HeLa cells was infected with
C. trachomatis serovar D, and IFN- was added at the time of infection
to induce persistence. At 38 hpi, persistent cultures were treated with
IFN-, doxycycline, L-1MT, or doxycycline with L-1MT for an addi-
tional 24 h. Following this, IFN-, doxycycline, and L-1MT were sub-
stituted for by culture medium supplemented with tryptophan (Trp)
and cycloheximide (CHX) for 48 h, after which recoverable IFU were
measured. (B) Recoverable IFU from persistent C. trachomatis cul-
tures from untreated control cells (white bar), cells treated with 0.2
mM L-1MT (gray bar), and cells treated with 1 g/ml doxycyline (black
bar) and 1 g/ml doxycyline with 0.2 mM L-1MT. N.D., not detectable
by the assay. Doxycycline or doxycycline with L-1MTwas added at 38
hpi, when persistence had been established on C. trachomatis cultures
treated with 10 ng/ml IFN-. Data represent means and standard
deviations from four independent experiments.
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monly imposed by antileishmanial therapy that targets replica-
tion (30). Our studies support the concept that partial restric-
tion of tryptophan availability may also increase the efficacy of
such drugs against Leishmania. Thus, our findings may provide
insights into the design of new therapeutic approaches that are
also more broadly applicable to many intracellular microor-
ganisms.
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